Sanofi enters the digital therapeutics market with MS app

The proposed app will aim to improve mental health in patients with multiple sclerosis. It was created in partnership with mental health digital therapeutics firm, Happify Health, with the app currently in a proof-of-concept online trial with several thousand MS patients. Statistics shows that MS patients are two- five times more likely to develop major depression than the general population.

After the results come through later this year, Sanofi plans to submit the app to the FDA for approval under the guise of a medical device. The app will be Sanofi’s first proposed digital therapeutic with MS carefully chosen due to Sanofi’s expertise in its understanding of the disease.

Sanofi has used its expertise in MS to incorporate specific medical and scientific needs into the base software platform by Happify Health, which is already in use for a non-specific solution in anxiety and depression with currently 4 million users.

This is Sanofis first move into the digital therapeutic area, but it is not the first pharma company. With the first FDA approved digital therapeutics product going to Pear Therapeutics reSET app to treat substance abuse, launched in partnership with Novartis Sandoz last year.

No comments:

Post a Comment

Coranavirus and its relationship with IP exclusivity

With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...